Resources
10 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 3/16/2022 (updated 3/27/2024)
Background: Sharp exacerbations of the US overdose crisis are linked to polysubstance use of synthetic compounds. Xylazine is a veterinary tranquilizer, long noted in the street opioid supply of Puerto Rico, and more recently Philadelphia. Yet its national trends, geographic distribution, and health risks are poorly characterized. Methods: In this sequential mixed-methods study, xylazine was increasingly observed by ethnographers in Philadelphia among drug-sellers and people who inject drugs (PWID). Subsequently, we systematically searched for records describing xylazine-present overdose mortality across the US and assessed time trends and overlap with other drugs
Posted 1/31/2023 (updated 3/27/2024)
The National Survey on Drug Use and Health (NSDUH) is conducted annual and provides nationally representative data on the use of substances (tobacco, alcohol, and drugs), substance use disorders, those who received substance use treatment, and mental health issues and services. This survey is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA).
Posted 2/28/2023 (updated 3/27/2024)
Researchers looked at records for 917 patients who engaged with a peer recovery coach via telehealth after discharge from emergency departments for opioid use. The investigation focused on one Indiana-based hospital system that included six hospitals located in cities and seven that had rural Critical Access Hospital designations.
Posted 11/19/2019 (updated 3/28/2024)
Telehealth offers the potential for increasing access and availability to addressing opioid overdose, and laws governing telehealth have implications for their utilization.
Posted 6/15/2020 (updated 3/28/2024)
The Center for Connected Health Policy’s (CCHP) Spring 2020 release of the “State Telehealth Laws and Reimbursement Policies” report highlights the changes that have taken place in state telehealth policy. The report offers policymakers, health advocates, and other interested health care professionals a summary guide of telehealth-related policies, laws, and regulations for all 50 states and the District of Columbia.
Posted 3/19/2020 (updated 3/28/2024)
To help local leaders respond to this epidemic, USDA has worked to build infrastructure for prevention, treatment and recovery, facilitate partnerships, and drive innovation in rural communities.
Posted 6/17/2021 (updated 4/2/2024)
Telemedicine is increasingly being used to treat patients with opioid use disorder (OUD). It has particular value in rural areas of the United States impacted by the opioid crisis as these areas have a shortage of trained addiction medicine providers. Patient satisfaction significantly impacts positive clinical outcomes in OUD treatment and thus is of great clinical interest.
Posted 3/1/2021 (updated 4/4/2024)
o CAST (calculating for an adequate system tool) produces community-specific assessments of the capacity of the components of a community substance abuse care system. CAST generates recommendations by the application of social and community determinants of health as risk coefficients to each estimate of component need. CAST can assist public health practitioners in evaluation and improvement of the capacity of community-based, substance abuse care systems.
Posted 3/2/2021 (updated 4/5/2024)
As state policymakers confront the substance use disorder (SUD) epidemic, they require a wide range of data – often found in disparate systems – to understand its impact and craft more effective treatment programs and interventions. This report explores best practices and sources for data gathering and describes how states can help communities access and use data to support local efforts.
Posted 4/12/2024
This peer reviewed journal article OUD treatment and pregnancy outcomes among pregnant patients receiving OUD care through a telehealth addiction treatment program in the US. The patients identified in the study received buprenorphine or buprenorphine and naloxone treatment.